Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQH3821 in Treated Rheumatoid Arthritis
NCT05849727Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing TQH3821 200 mg with Placebo -> TQH3821 (2 arms). Primary endpoint: American College of Rheumatology 20 improvement at 12 weeks. Started Aug 2023; status: terminated.
02
Drugs
tqh3821
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05849727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849727.